SIBO
INSTITUTE
Treatment · 9 min read

SIBO Treatment Phases

# Reduce, Restore, Rebuild: Why SIBO Treatment Isn't One-Size-Fits-All

Editorial DeskJan 2026
SIBO Treatment Phases

Reduce, Restore, Rebuild: Why SIBO Treatment Isn't One-Size-Fits-All

A realistic look at how recovery actually works — and why the same protocol rarely works the same way twice.

SIBO is often presented as though there is a single protocol: take an antibiotic, follow a diet, add a probiotic, and move on. In reality, treatment is rarely that straightforward.

Some people improve after a single course of therapy. Others require several attempts, different treatment combinations, or months of careful adjustments before symptoms begin to stabilize. This variability is one of the most frustrating aspects of living with SIBO — and one of the reasons patients often lose confidence after an unsuccessful treatment.

Current research suggests there is no universal roadmap that works for everyone. Instead, successful management usually involves three things happening together: reducing bacterial overgrowth, restoring normal intestinal function, and addressing the underlying reason the overgrowth developed in the first place.

Phase One — Reduce

The first objective is to decrease the bacterial or archaeal burden within the small intestine. How that's done depends heavily on which gases showed up on testing.

For hydrogen-predominant SIBO, rifaximin remains the most extensively studied antibiotic. It's poorly absorbed, meaning it acts mostly within the gut rather than systemically, which is part of why it's become the default first-line option. Reported eradication rates vary by study and dose — figures in the literature range from roughly 47% to 73%, with a pooled estimate closer to 59%, and moderate-to-high doses (1,200 mg/day and above) tending to slightly outperform lower doses. That range matters: it means a meaningful share of people won't clear SIBO on a first course, and that isn't a sign anything was done wrong.

Methane-predominant overgrowth — now more precisely called Intestinal Methanogen Overgrowth, or IMO — often requires combination therapy, because methanogens are archaea, not bacteria, and respond differently to antimicrobial treatment. Rifaximin alone has shown limited methane-clearance rates in trials (as low as 28% in one study), while adding neomycin to rifaximin has been shown to substantially improve outcomes — one trial found 87% methane eradication and 85% clinical response with the combination, compared to much lower rates with either drug alone. Even patients who fail rifaximin on its own often respond once neomycin is added.

Some clinicians also use herbal antimicrobial protocols — combinations like berberine, oregano oil, neem, or allicin — although the quality of evidence supporting these approaches is considerably more limited than prescription therapies. The most-cited comparison, a 2014 retrospective study, found herbal therapy performed comparably to rifaximin (46% versus 34% negative follow-up breath tests), and notably, 57% of patients who had failed rifaximin went on to respond to the herbal protocol. But this was a retrospective, non-randomized study with a real risk of bias — it suggests herbal options are reasonable to consider, not that they're proven equivalent.

In selected situations, elemental diets — liquid formulas that supply nutrition in a pre-digested form the small intestine can absorb before bacteria get to it — may also be considered under medical supervision, typically for short, defined periods.

No single approach consistently outperforms every other, because patients differ. Breath test results, underlying medical conditions, prior treatment history, medication tolerance, and symptom severity all influence which strategy may be most appropriate. The goal during this phase is symptom improvement — not perfection.

Phase Two — Restore

For many people, eliminating bacterial overgrowth is only part of the solution. If nothing changes about the intestinal environment that allowed bacteria to accumulate in the first place, they simply move back in.

One of the most overlooked contributors to recurrent SIBO is impaired intestinal motility, particularly dysfunction of the Migrating Motor Complex (MMC). This rhythmic wave of muscular contractions sweeps residual food and bacteria out of the small intestine between meals — think of it as housekeeping that only runs while you're not eating. When this process becomes impaired, bacteria have far more opportunity to accumulate and persist.

Impaired MMC function is considered the primary driver of SIBO recurrence after antimicrobial treatment — which is why "restore" often matters as much as "reduce."

Motility can become impaired after food poisoning, abdominal surgery, diabetes, connective tissue disorders, or other conditions that damage the nerves and muscles coordinating gut movement. Depending on the individual, treatment during this phase may include:

  • Prescription prokinetics — low-dose erythromycin, low-dose prucalopride, or low-dose naltrexone (LDN) are the options most commonly discussed for supporting the MMC between meals
  • Botanical prokinetics — ginger and other traditional motility-supporting compounds, generally considered gentler but less extensively studied
  • Meal spacing — allowing real gaps between meals so the MMC has a chance to complete its sweeping cycle, rather than grazing throughout the day
  • Sleep, movement, and stress reduction — all of which influence the autonomic nervous system that helps regulate gut motility
  • Addressing other conditions that independently slow transit, such as thyroid dysfunction or diabetes

Prokinetic use is often framed as a multi-month commitment rather than a quick fix — many protocols suggest continuing for at least three months before reassessing, since the MMC needs sustained support to recover, not just a single nudge. The objective is to create an intestinal environment that discourages recurrence, rather than repeatedly treating the consequences.

Phase Three — Rebuild

Recovery does not end when symptoms begin improving.

Many patients have significantly restricted their diets before receiving a diagnosis. Others develop understandable anxiety around eating after months of bloating or pain. Gradually expanding food choices, correcting nutritional deficiencies where present, and restoring confidence around eating become important parts of long-term recovery — arguably the part that gets the least attention, even though it's often the hardest.

For some patients, probiotics may be appropriate. For others, they may worsen symptoms or provide little measurable benefit. Current research remains genuinely mixed on this — some studies describe a therapeutic role for probiotics, prebiotics, and synbiotics in SIBO, while clinical experience shows highly individual responses. Recommendations here should be individualized rather than universally applied, and "try it and see how your body responds" is a reasonable approach, provided it's a small, deliberate trial rather than an indefinite guess.

Likewise, dietary approaches such as the low-FODMAP diet are intended to reduce symptoms temporarily — not become permanent lifestyles. Long-term, unnecessarily restrictive eating can itself create new problems: nutrient gaps, a shrinking list of "safe" foods, and a harder relationship with food generally. The ultimate objective is always the broadest, most nutritionally complete diet a person can comfortably tolerate — expanded deliberately, one food at a time, rather than all at once.

The Root Cause Matters

Perhaps the most important lesson emerging from modern SIBO research is that bacterial overgrowth is often a consequence rather than the primary disease itself.

Post-infectious motility damage appears to be the single most common underlying cause. Food poisoning can trigger the body to produce autoantibodies (anti-vinculin and anti-CdtB antibodies have both been studied) that mistakenly target the nerve cells controlling the MMC — a process sometimes called post-infectious IBS, and thought to account for a large share of cases.

Other underlying contributors may include:

  • Structural issues — adhesions (scar tissue) from previous abdominal surgery, which can subtly obstruct normal flow and give bacteria a place to accumulate
  • Systemic conditions — hypothyroidism, diabetes, and connective tissue disorders like scleroderma, all of which can slow gut transit
  • Inflammatory bowel disease, which alters gut anatomy and immune activity
  • Medication effects — long-term proton pump inhibitor (PPI) use reduces stomach acid, removing a natural barrier to bacterial migration; opioids slow motility directly
  • Nervous system disorders affecting the signals that regulate digestion

Unless these factors are identified and addressed where possible, recurrence becomes considerably more likely. Treating SIBO without investigating why it developed is often like mopping water off the floor while ignoring the leaking pipe.

The Reality

One of the most difficult truths about SIBO is that there is rarely a perfect protocol.

A treatment that produces complete resolution for one patient may produce only modest improvement — or no improvement at all — for another. Scientific evidence continues to evolve, but clinicians still do not fully understand why responses vary so dramatically between individuals. Even after "successful" treatment, recurrence is common: some observational data puts relapse rates around 40–45% within a follow-up period, which is part of why the restore and rebuild phases matter as much as the initial reduce phase.

That uncertainty can be discouraging. It can also leave patients feeling as though they have somehow failed treatment.

They haven't.

SIBO is a complex disorder with multiple causes, multiple presentations, and multiple treatment pathways. Progress is often measured over months rather than weeks, and improvement commonly occurs through thoughtful adjustments rather than a single breakthrough.

The Takeaway

Recovery from SIBO is rarely linear. It is a process of reducing overgrowth, restoring intestinal function, rebuilding digestive resilience, and addressing the factors that allowed the condition to develop in the first place. The best treatment plan is not necessarily the most aggressive one — it is the one that is individualized, evidence-informed, and adaptable as new information emerges.

At SIBO Institute, our goal is to provide balanced, evidence-based education without promising quick fixes or one-size-fits-all solutions. As research continues to evolve, we remain committed to helping patients better understand the complexity of SIBO and navigate recovery with clarity, realistic expectations, and informed decision-making.

This article is for general educational purposes and isn't a substitute for medical advice, diagnosis, or treatment. Work with a qualified healthcare provider to design and adjust any SIBO treatment plan.

References

SIBO Institute Editorial
Continue reading
SIBO Supplements: What Actually Helps (Hydrogen vs. Methane Guide)
SIBO Supplements: What Actually Helps (Hydrogen vs. Methane Guide)
Probiotics and Prebiotics for SIBO: A Complete, Strain-by-Strain Guide
Probiotics and Prebiotics for SIBO: A Complete, Strain-by-Strain Guide
Stay informed

Knowledge is the first step to healing.

A weekly editorial from the Institute — new research, considered recipes, and practical tools. No noise. No sales pitch. Just the essentials.

Free. Unsubscribe with one click.